ArticleCaspian journal of internal medicine2026
Survival rate in patients with pancreatic cancer in Guilan province, Iran.
Article in Caspian journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is among the deadliest malignancies globally, marked by poor prognosis and limited survival. This research investigated the demographic and clinical determinants affecting overall survival in patients diagnosed with pancreatic cancer in Guilan Province, Iran. Methods: A total of 50 pathologically and radiologically confirmed cases of pancreatic cancer were analyzed. Demographic, anthropometric, and clinical data were extracted from medical records. Survival probabilities were estimated using the Kaplan--Meier method, and intergroup differences were tested using the log-rank test. Cox proportional hazards modeling identified predictors of mortality, with significance defined at Results: The majority of patients were male (60%) and over 60 years old (58%), while 46% had normal BMI and 40% had blood group O. Comorbidities were present in 42%, and 32% were diagnosed at stage IV. Mean and median survival were 39.6 and 9.0 months, respectively. One-, three-, and five-year survival rates were 45.2%, 31.3%, and 23.5%. Advanced tumor stage (III/IV) significantly predicted shorter survival (p < 0.001). Underweight individuals had higher mortality risk (HR = 2.79; 95% CI: 1.21--6.42; P = 0.016). In multivariate models, male gender, blood group O, and advanced disease remained independent negative prognostic indicators. Conclusion: Male sex, advanced stage, low BMI, and blood group O were major determinants of poorer survival in pancreatic cancer. These results emphasize the need for individualized treatment and closer follow-up among high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.